Dipartimento di Scienze Mediche e Chirurgiche, Università degli Studi "Magna Græcia", Catanzaro, Italy.
Dipartimento di Scienze Cardio-Toraciche e Respiratorie, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy.
Biomed Res Int. 2018 May 10;2018:4839230. doi: 10.1155/2018/4839230. eCollection 2018.
Asthma is a very frequent chronic airway disease that includes many different clinical phenotypes and inflammatory patterns. In particular, eosinophilic bronchial inflammation is often associated with allergic as well as nonallergic asthma. The most important cytokine involved in the induction, maintenance, and amplification of airway eosinophilia in asthma is interleukin-5 (IL-5), released by both T helper 2 (Th2) lymphocytes and group 2 innate lymphoid cells (ILC2). Hence, IL-5 and its receptor are suitable targets for selective biologic drugs which can play a key role in add-on treatment of severe eosinophilic asthma refractory to corticosteroids. Within such a context, the anti-IL-5 monoclonal antibodies mepolizumab and reslizumab have been developed and approved for biological therapy of uncontrolled eosinophilic asthma. In this regard, on the basis of several successful randomized controlled trials, the anti-IL-5 receptor benralizumab has also recently obtained the approval from US Food and Drug Administration (FDA).
哮喘是一种非常常见的慢性气道疾病，包括许多不同的临床表型和炎症模式。特别是，嗜酸性支气管炎症通常与过敏性和非过敏性哮喘有关。在哮喘中诱导、维持和放大气道嗜酸性粒细胞浸润的最重要细胞因子是白细胞介素-5（IL-5），它由辅助性 T 细胞 2（Th2）淋巴细胞和 2 型固有淋巴细胞（ILC2）释放。因此，IL-5 和它的受体是选择性生物药物的合适靶点，这些药物在治疗对皮质类固醇难治的严重嗜酸性粒细胞性哮喘的附加治疗中可以发挥关键作用。在这种情况下，抗白细胞介素-5 单克隆抗体美泊利珠单抗和瑞利珠单抗已被开发并批准用于治疗控制不佳的嗜酸性粒细胞性哮喘的生物治疗。在这方面，基于几项成功的随机对照试验，抗白细胞介素-5 受体贝那利珠单抗最近也获得了美国食品和药物管理局（FDA）的批准。
